Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Brian Tomlinson, Paul Chan & Christopher Wai Kei Lam. (2022) An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:1, pages 29-42.
Read now
Read now
Kazuki Orime & Yasuo Terauchi. (2020) Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 21:17, pages 2101-2114.
Read now
Read now
Jingbo Hu, Chunlin Yang, Hongbo Wang, Jing Li, Xueying Tan, Jinhui Wang, Bin Zhang & Yufen Zhao. (2019) An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 20:14, pages 1679-1687.
Read now
Read now
André Jacques Scheen. (2018) The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety 17:4, pages 387-405.
Read now
Read now
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Makoto Ueno, Miyuki Matsukawa, Tomoko Yamakura, Kazuyo Sasaki, Mayumi Kimura & Hiroaki Iijima. (2018) Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 19:2, pages 83-91.
Read now
Read now
André J. Scheen. (2017) Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology 10:12, pages 1303-1316.
Read now
Read now
André J. Scheen. (2017) Pharmacological management of type 2 diabetes: what’s new in 2017?. Expert Review of Clinical Pharmacology 10:12, pages 1383-1394.
Read now
Read now
Sayf A Yassin & Vanita R Aroda. (2017) Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy 11, pages 923-937.
Read now
Read now
Jayant Dey. (2017) SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus. Postgraduate Medicine 129:4, pages 409-420.
Read now
Read now
Tomas Lafarga & Maria Hayes. (2017) Bioactive protein hydrolysates in the functional food ingredient industry: Overcoming current challenges. Food Reviews International 33:3, pages 217-246.
Read now
Read now
André J. Scheen. (2017) Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:5, pages 583-592.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 211-223.
Read now
Read now
André J. Scheen. (2016) DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1407-1417.
Read now
Read now
Zheng Li, Qianqian Qiu, Xinqian Geng, Jianyong Yang, Wenlong Huang & Hai Qian. (2016) Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opinion on Investigational Drugs 25:8, pages 871-890.
Read now
Read now
Rose Anderson, Jennifer Hayes & Jeffrey W. Stephens. (2016) Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 467-473.
Read now
Read now
André J. Scheen. (2016) Investigational insulin secretagogues for type 2 diabetes. Expert Opinion on Investigational Drugs 25:4, pages 405-422.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 25:2, pages 145-158.
Read now
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Read now
Articles from other publishers (63)
Sabry M. Attia, Sheikh F. Ahmad, Ahmed Nadeem, Mohamed S.M. Attia, Mushtaq A. Ansari, Abdelkader E. Ashour, Norah A. Albekairi, Mohammed A. Al-Hamamah, Ali A. Alshamrani & Saleh A. Bakheet. (2023) Saxagliptin, a selective dipeptidyl peptidase-4 inhibitor, alleviates somatic cell aneugenicity and clastogenicity in diabetic mice. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 892, pages 503707.
Crossref
Crossref
Martin Haluzík, Iva Jakubíková, Michaela Kudláčková & Luděk Horváth. (2023) Current options for the treatment of obesity. Medicína pro praxi 20:4, pages 230-234.
Crossref
Crossref
Hitoshi Ishii, Nozomu Kamei, Dai Shimono, Tetsuji Niiya, Takahiro Tosaki, Toru Kitazawa, Daisuke Suzuki, Yutaka Wakasa, Hiroaki Seino, Mariko Oishi, Hiroshi Ohashi, Kenshi Higami & Hiroaki Akai. (2023) Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study). Diabetes Therapy.
Crossref
Crossref
Sunayana Vikhe, Rahul Kunkulol & Dipak Raut. (2023) In Silico and In Vivo Studies of Decursin Isolated From the Ethanolic
Extract of Feronia elephantum Correa (Rutaceae) Bark as a Potential Antidiabetic
and Antihyperlipidemic Agents in STZ-induced Diabetic Rats. Letters in Drug Design & Discovery 20:5, pages 517-535.
Crossref
Crossref
Victoria Ojonogecha Idoko, Mohammed Aliyu Sulaiman, Rahma Muhammad Adamu, Aliyu Dantani Abdullahi, Nasir Tajuddeen, Aminu Mohammed, Hajiya Mairo Inuwa & Mohammed Auwal Ibrahim. (2023)
Evaluating
Khaya senegalensis
for Dipeptidyl Peptidase‐IV Inhibition Using
in Vitro
Analysis and Molecular Dynamic Simulation of Identified Bioactive Compounds
. Chemistry & Biodiversity 20:2.
Crossref
Crossref
Pallavi Kishor Vawhal, Shailaja B. Jadhav, Sumit Kaushik, Kahnu Charan Panigrahi, Chandan Nayak, Humaira Urmee, Sharuk L. Khan, Falak A. Siddiqui, Fahadul Islam, Aziz Eftekhari, Abdullah R. Alzahrani, Mohd Fahami Nur Azlina, Md. Moklesur Rahman Sarker & Ibrahim Abdel Aziz Ibrahim. (2023) Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay. Molecules 28:3, pages 1004.
Crossref
Crossref
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan & J. Chimakurthy. (2023) Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes. Journal of Endocrinological Investigation 46:5, pages 855-867.
Crossref
Crossref
Leslie Bahn Kawa. 2023. Type 2 Diabetes - From Diagnosis to Effective Management [Working Title]. Type 2 Diabetes - From Diagnosis to Effective Management [Working Title].
Sheng-Li Wu, Chen-Chen Zhang, Ji-Jun Chen, Xue-Mei Zhang, Min Guan & Chang-An Geng. (2022) Oligostilbenes from the seeds of Paeonia lactiflora as potent GLP-1 secretagogues targeting TGR5 receptor. Fitoterapia, pages 105336.
Crossref
Crossref
Ajinkya Chavan, Kratika Daniel & Ansar M. Patel. (2022) In-silico Exploration of Phytoconstituents of Gymnema sylvestre as Potential
Glucokinase Activators and DPP-IV Inhibitors for the Future Synthesis
of Silver Nanoparticles for the Treatment of Type 2 Diabetes Mellitus. Current Enzyme Inhibition 18:1, pages 47-60.
Crossref
Crossref
Prerana A. Chavan & Shailaja B. Jadhav. (2022) Synthesis, Characterization and Screening of Some Novel 2-Methyl-N'-
[(Z)-Substituted-Phenyl ethylidene] Imidazo [1, 2-a] Pyridine-3-Carbohy
drazide Derivatives as DPP-IV Inhibitors for the Treatment of Type 2 Diabetes
Mellitus. Letters in Drug Design & Discovery 19:2, pages 160-174.
Crossref
Crossref
Siwen Wang, Ting Wu, Zhihong Zuo, Ping Jin, Xuan Luo & Meichun Deng. (2021) Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis. European Journal of Preventive Cardiology 28:16, pages 1840-1849.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
323
342
.
André J. Scheen. (2021) Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes & Metabolism 47:6, pages 101275.
Crossref
Crossref
Sheriza Baksh, Jiajun Wen, Omar Mansour, Hsien-Yen Chang, Mara McAdams-DeMarco, Jodi B. Segal, Stephan Ehrhardt & G. Caleb Alexander. (2021) Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study. Scientific Reports 11:1.
Crossref
Crossref
Stephan Jacob, Andrew J. Krentz, John Deanfield & Lars Rydén. (2021) Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs 81:12, pages 1373-1379.
Crossref
Crossref
Lisa Clark, Erin Weeda, Mary Lewis Griffin, Lee Ann Jones & Jason Haney. (2019) Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients With Prediabetes or Diabetes After Cardiac Surgery. Journal of Pharmacy Practice 34:2, pages 259-264.
Crossref
Crossref
Madhan Shanmugasundaram, J. R. Exequiel Pineda & Sangeetha Murugapandian. (2021) Glucose-Lowering Medications and Cardiovascular Outcomes. Current Cardiology Reports 23:4.
Crossref
Crossref
Linong Ji, Ling Li, Jianhua Ma, Xuefeng Li, Dongmei Li, Bangzhu Meng, Weiping Lu, Jiao Sun, Yanmei Liu, Gen Takayanagi & Yi Wang. (2021) Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study. Endocrinology, Diabetes & Metabolism 4:2.
Crossref
Crossref
Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula A. Paschou, Evangelos Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis & Dimitrios Tousoulis. (2020) Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Current Pharmaceutical Design 26:46, pages 5911-5932.
Crossref
Crossref
Sheriza N. Baksh, Jodi B. Segal, Mara McAdams-DeMarco, Rita R. Kalyani, G. Caleb Alexander & Stephan Ehrhardt. (2020) Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease. PLOS ONE 15:10, pages e0240141.
Crossref
Crossref
Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi & Manfredi Rizzo. (2020) Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism 111, pages 154343.
Crossref
Crossref
Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolic, Angelo Maria Patti & Ali A. Rizvi. (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 109, pages 154295.
Crossref
Crossref
Yuwen Cai, Xin Liu & Gaosi Xu. (2020) Combination therapy with SGLT2 inhibitors for diabetic kidney disease. Biomedicine & Pharmacotherapy 127, pages 110192.
Crossref
Crossref
Martin Haluzík. (2020) Incretin-based treatment of diabetes and cardiovascular complications. Vnitřní lékařství 66:2, pages 74-80.
Crossref
Crossref
Qi Liao, Lan Jiang, Cong Li, Yaling Shen, Min Wang, Chengkun Cao & Xiangnan Hu. (2019) An Efficient and Practical Method for the Synthesis of Saxagliptin Intermediate 2-(3-Hydroxy-1-adamantane)-2-oxoacetic Acid and Its Optimization. Journal of Chemistry 2019, pages 1-8.
Crossref
Crossref
Hiroki Yoshioka, Yui Hirose, Rurika Ohishi, Sarah Tominaga, Aya Torii-Goto, Sang Jun Park, Nobuhiko Miura & Masae Yoshikawa. (2019) Diurnal Variation of Sitagliptin-Induced Pharmacological Effects in C57BL/6J Mice. Biological and Pharmaceutical Bulletin 42:9, pages 1562-1568.
Crossref
Crossref
Mirza Muhammad Faran Ashraf Baig, Muhammad Naveed, Muhammad Abbas, Wen Chunxia, Sana Ullah, Muhammad Hasnat, Asam Shad, Muhammad Sohail, Ghulam Jilany Khan & Muhammad Tayyab Ansari. (2019) DNA scaffold nanoparticles coated with HPMC/EC for oral delivery. International Journal of Pharmaceutics 562, pages 321-332.
Crossref
Crossref
Yuta Yamamoto, Yutaro Yamamoto, Tetsuya Saita & Masashi Shin. (2019) Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine. ACTA HISTOCHEMICA ET CYTOCHEMICA 52:1, pages 27-34.
Crossref
Crossref
Ji-Yeon LeeEun Seok Kang. (2019)
Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (
Diabetes Metab J
2019;43:158–73)
. Diabetes & Metabolism Journal 43:3, pages 379.
Crossref
Crossref
Solomon Habtemariam. 2019. Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases. Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases
89
107
.
Nurhayat Ozkan Sevencan, Aysegul Ertinmaz Ozkan & Burcak Kayhan. (2018) Linagliptin-related pancreatitis in a diabetic patient with biliary calculus. Medicine 97:50, pages e13284.
Crossref
Crossref
Gabrielle Kéfrem Alves Gomes, Aline Istéfane de Camargos Ramos, Camila Tavares de Sousa, Cristina Sanches, Mariana Linhares Pereira & André Oliveira Baldoni. (2018) Linagliptin safety profile: A systematic review. Primary Care Diabetes 12:6, pages 477-490.
Crossref
Crossref
Lawrence Blonde, Susana Dipp & Daniel Cadena. (2018) Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Advances in Therapy 35:7, pages 939-965.
Crossref
Crossref
André J. Scheen. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research 122:10, pages 1439-1459.
Crossref
Crossref
Rosa Suades, Francesco Cosentino & Lina Badimon. (2018) Glucose-lowering treatment in cardiovascular and peripheral artery disease. Current Opinion in Pharmacology 39, pages 86-98.
Crossref
Crossref
Honghong Zou, Baoqin Zhou & Gaosi Xu. (2017) SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Ira Gantz, Taro Okamoto, Yuka Ito, Kotoba Okuyama, Edward A. O'Neill, Keith D. Kaufman, Samuel S. Engel & Eseng Lai. (2017) A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 19:11, pages 1602-1609.
Crossref
Crossref
F. Bonnet & A.J. Scheen. (2017) Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. Diabetes & Metabolism 43:4, pages 299-313.
Crossref
Crossref
Zeynep Mine Coskun, Meral Koyuturk, Sezin Karabulut & Sema Bolkent. (2017) CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin. Pharmacological Reports 69:4, pages 822-829.
Crossref
Crossref
Ildiko Lingvay. (2017) Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo. Endocrine Practice 23:7, pages 831-840.
Crossref
Crossref
James Thrasher. (2017) Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. The American Journal of Cardiology 120:1, pages S4-S16.
Crossref
Crossref
André J. Scheen. (2016) Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clinical Pharmacokinetics 56:7, pages 703-718.
Crossref
Crossref
Bhumika D. Patel, Shraddha V. Bhadada & Manjunath D. Ghate. (2017) Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors. Bioorganic Chemistry 72, pages 345-358.
Crossref
Crossref
James Thrasher. (2017) Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. The American Journal of Medicine 130:6, pages S4-S17.
Crossref
Crossref
André J. Scheen. (2017) Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Research and Clinical Practice 127, pages 224-237.
Crossref
Crossref
Peter L. Thompson & Timothy M.E. Davis. (2017) Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. Clinical Therapeutics 39:5, pages 1012-1025.
Crossref
Crossref
Andrew J. Krentz & Alan J. Sinclair. 2017. Diabetes in Old Age. Diabetes in Old Age
298
322
.
John B. Buse, M. Angelyn BethelJennifer B. Green, Susanna R. Stevens, Yuliya Lokhnygina, Pablo Aschner, Carlos Raffo Grado, Tsvetalina Tankova, Julio Wainstein, Robert Josse, John M. Lachin, Samuel S. Engel, Keyur Patel, Eric D. Peterson & Rury R. Holman. (2017) Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care 40:2, pages 164-170.
Crossref
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.
Maeve Lynch, Tomás B. Ahern, Irene Timoney, Cheryl Sweeney, Genevieve Kelly, Rosalind Hughes, Anne-Marie Tobin, Donal O’Shea & Brian Kirby. (2016) Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. Trials 17:1.
Crossref
Crossref
Andrew J. Krentz. (2016) Hypertension in type 2 diabetes: impact of glucose-lowering medications. Cardiovascular Endocrinology 5:4, pages 137-143.
Crossref
Crossref
André J. Scheen. (2016) Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Research and Clinical Practice 121, pages 204-214.
Crossref
Crossref
André J. Scheen. (2016) Precision medicine: The future in diabetes care?. Diabetes Research and Clinical Practice 117, pages 12-21.
Crossref
Crossref
Oleg G. Chepurny, George G. Holz, Michael W. Roe & Colin A. Leech. (2016) GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion. Molecular Endocrinology 30:6, pages 614-629.
Crossref
Crossref
S. Del Prato, P. Fleck, C. Wilson & P. Chaudhari. (2016) Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 18:6, pages 623-627.
Crossref
Crossref
Sven Kohler, Afshin Salsali, Stefan Hantel, Stefan Kaspers, Hans J. Woerle, Gabriel Kim & Uli C. Broedl. (2016) Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. Clinical Therapeutics 38:6, pages 1299-1313.
Crossref
Crossref
Avivit Cahn, Simona Cernea & Itamar Raz. (2016) Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Reviews in Endocrine and Metabolic Disorders 17:1, pages 117-127.
Crossref
Crossref
Zhengchao Xia, Hongyan Wei, Jingjing Duan, Ting Zhou, Zhen Yang & Feng Xu. (2016) Chronic unpredicted mild stress-induced depression alter saxagliptin pharmacokinetics and CYP450 activity in GK rats. PeerJ 4, pages e1611.
Crossref
Crossref
Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas Seck, Sanjay Patel, Hans-Juergen Woerle & Odd Erik Johansen. (2015) Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Damon A. Bell & Gerald F. Watts. (2015) Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics 37:12, pages 2732-2750.
Crossref
Crossref
André J. Scheen. (2015) Author’s Reply to De Ponti et al.: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”. Clinical Pharmacokinetics 54:4, pages 449-451.
Crossref
Crossref
Vladimir Pech, Khalid Abusaada & Carlos Alemany. (2015) Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor. Case Reports in Endocrinology 2015, pages 1-3.
Crossref
Crossref